class = “cf”>
A consensus has been reached in the case of the vaccine supply between the European Union (EU) and AstraZeneca, which is producing a new type of vaccine against the coronavirus (Kovid-19).
The European Commission has announced that legal proceedings it has initiated against pharmaceutical company AstraZeneca over delays in the supply of the Kovid-19 vaccine have ended by agreement between the parties.
In the statement, recalling that AstraZeneca delivered around 100 million doses of vaccine to the EU at the end of the second quarter, as part of the agreement, a total of 135 million doses of vaccine until the end of 2021 , 60 million doses through the end of the third trimester and 75 million doses through the end of the fourth trimester. It was noted that it is committed to supply.
In addition, it was said in the statement that AstraZeneca will deliver 65 million doses of vaccine to the EU by the end of March next year.
In the statement, it was reported that the company will regularly deliver vaccines to EU member countries and apply a discount on the price of the vaccine if there is a delay.
class = “cf”>
The EU’s agreement with AstraZeneca in August 2020 provided for the supply of 300 million doses of vaccine and the possibility of purchasing an additional 100 million doses on demand.
While the EU expected 120 million doses of the vaccine in the first quarter of the year, the company was only able to deliver 30 million doses. In the second quarter, the European side expected 180 million doses, but the company said it could deliver 70 million doses during that time.
The European Commission wanted AstraZeneca to also ship vaccines produced at its facilities in non-EU countries to EU countries.
The company, on the other hand, has said it is committed to making as much effort as possible in this regard, not the amount and date of delivery to the EU in concrete terms.
In April, the European side filed a complaint against AstraZeneca in the Brussels court for breach of the vaccine purchase agreement and supply delays.
The European Medicines Agency (EMA) has so far authorized the use of vaccines produced by the companies Pfizer / Biontech, Moderna, AstraZeneca and Johnson & Johnson in EU countries.
The EU administration announced this week that 70 percent of adults in member states are fully vaccinated.
This guide guides gastronomy enthusiasts